Log in
Enquire now
‌

US Patent 10258619 Combination therapy with glutaminase inhibitors and immuno-oncology agents

Patent 10258619 was granted and assigned to Calithera Biosciences on April, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Patent abstract

The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10258619 Combination therapy with glutaminase inhibitors and immuno-oncology agents

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.